AI assistant
NOXOPHARM LIMITED — Share Issue/Capital Change 2016
Dec 18, 2016
65437_rns_2016-12-18_fe8d04f5-bfc7-4a2d-91ae-e6ac5008d0cc.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
==> picture [180 x 77] intentionally omitted <==
Date 19 December 2016
ASX: NOX
Noxopharm Limited
MARKET CAPITALISATION
The Company wishes to advise shareholders that the $50 million market capitalisation performance critera has been satisfied.
ABN 50 608 966 123
Registered Office:
Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia
Board of Directors Mr Peter Marks Chairman Non‐Executive Director
Dr Graham Kelly Chief Executive Officer Managing Director
Dr Ian Dixon Non‐Executive Director
Having achieved the milestone the company has converted performance shares into 10m unlisted ordinary shares, subject to escrow until August 2018.
The updated issued capital of the company is as follows:
| Unlisted | Listed | ||
|---|---|---|---|
| Listed Fully PaidOrdinary Shares | 33,560,000 | ||
| Unlisted Ordinaryshares | Subject to escrowuntil 08 Jan 2017 | 464,750 | |
| Unlisted Ordinaryshares | Subject to escrowuntil 01 Apr 2017 | 4,261,214 | |
| Unlisted Ordinaryshares | Subject to escrowuntil 09 Aug 2018 | 46,885,465 | |
| Unlisted Options$0.30 Expiry 28/02/21 | Subject to escrowuntil 09 Aug 2018 | 18,950,358 | |
| Unlisted Options$0.30 Expiry 28/02/21 | Subject to escrowuntil 08 Jan 2017 | 357,500 | |
| Unlisted Options$0.30 Expiry 28/02/21 | Subject to escrowuntil 01 Apr 2017 | 3,277,858 |
Listed Shares: 33,560,000 Unlisted Options: 22,585,716 Unlisted Shares: 51,611,429
==> picture [58 x 49] intentionally omitted <==
Phillip Hains Company Secrtary
About The Blood‐Brain Barrier
The blood‐brain barrier exists in the blood vessels in the brain, where the endothelial cells lining the blood vessels are more tightly joined than in the rest of the body, joined by brain cells known as glial cells that control the inflow of compounds into the brain. Together these two layers ensure that passive diffusion of compounds into the brain is limited to water, some gases and a small number of compounds. Everything else, including drugs, is subject to active transport mechanisms which are highly selective. Some 98% of human drugs fail to cross the blood‐brain barrier because of the absence of active transporters specific for those drugs.
About Noxopharm
Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug‐resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.
About NOX66
NOX66 is an innovative dosage formulation of the experimental anti‐cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. Its purpose is to ensure that most idronoxil administered remains in the body in an active form. Idronoxil works by cancelling pro‐survival mechanisms in cancer cells regulated by sphingosine‐1‐phosphate, a key pro‐survival mechanism that allows cancer cells to resist the killing effects of chemotherapies and radiotherapy.
INVESTOR AND MEDIA ENQUIRIES: Prue Kelly E: [email protected] T: + 61 2 9144 2223
Forward Looking Statements
This announcement may contain forward‐looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward‐looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward‐looking statements to be reasonable, they are not certain. Forward‐looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward‐looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward‐looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.